Innoviva

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time. A live webcast of the fireside chat can be accessed under “Events & Presentation

Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

La Jolla Pharmaceutical

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”), net to the seller in cash, without interest and less required withholding taxes

Innoviva Completes Acquisition of La Jolla Pharmaceutical

Innoviva (INVA) delivered earnings and revenue surprises of -90.91% and 4.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Misses Q2 Earnings Estimates

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022. Gross royalty revenues of $111.7 million from Glaxo Group Limited (“GSK”) for the second quarter of 2022 included royalties of $59.3 million from global net sal

Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Innoviva (INVA) Q2 Earnings Expected to Decline

Theravance Biopharma

Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK plc's (NYSE: GSK) TRELEGY ELLIPTA to Royalty.

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

Royalty Pharma

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company LLC (“TRC”), which receives royalties stemming from sales of TRELEGY® ELLIPTA®, to Royalty Pharma plc (Nasdaq: RPRX) for an upfront cash payment of approximately $282 millio

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment

Wilmington, Delaware--(Newsfile Corp. - July 12, 2022) - Rigrodsky Law, P.A. is investigating La Jolla Pharmaceuticals Company ("La Jolla") (NASDAQ: LJPC) regarding possible breaches of fiduciary duties and other violations of law related to La Jolla's agreement to be acquired by Innoviva Inc. (NASDAQ: INVA). Under the terms of the agreement, La Jolla's shareholders will receive $6.23 in cash for each share of La Jolla common stock they own.To learn more about this investigation...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating La Jolla Pharmaceuticals Company Buyout

NEW YORK , July 11, 2022 /PRNewswire/ --  Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical Company ("La Jolla" or the "Company") (NASDAQ: LJPC) in connection with the proposed acquisition of the Company by Innoviva, Inc. (NASDAQ: INVA) via tender offer.  Under the terms of the merger agreement, the Company's shareholders will receive $6.23 in cash for each share of La Jolla common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of La Jolla Pharmaceutical Company (NasdaqCM: LJPC) to Innoviva, Inc. (NasdaqGS: INVA). Under the terms of the proposed transaction, shareholders of La Jolla will receive only $6.23 in cash for each share of La Jolla that they own. KSF is seeking to determine whether this consideration and the process that led to

LA JOLLA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of La Jolla Pharmaceutical Company - LJPC

A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders. The post La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News appeared first on InvestorPlace.

La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products. Entasis brings to Innoviva an exciting portfolio that includes potentially first- and best-in-class medicines for

Innoviva Completes Acquisition of Entasis Therapeutics

Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional.

Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acqui

Innoviva to Acquire La Jolla Pharmaceutical Company

Entasis Therapeutics Holdings Inc

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022. The depositary for the tender offer has advised that, as of the exp

Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the directors of Entasis Therapeutics Holdings Inc. (“Entasis”) (NASDAQ: ETTX) breached their fiduciary duties to its shareholders in approving a buyout with Innoviva, Inc. (“Innoviva”) (NASDAQ: INVA) for inadequate consideration. If you are an Entasis shareholder, you may contact attorney Joe Pettigrew for additional information

Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX

NEW YORK , May 24, 2022 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) and its board of directors concerning the proposed acquisition of the company by Innoviva, Inc. (NASDAQ: INVA). Stockholders will receive $2.20 for each share of Entasis Therapeutics Holdings stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Entasis Therapeutics Holdings Inc. (NasdaqGM: ETTX) to Innoviva, Inc. (NasdaqGS: INVA). Under the terms of the proposed transaction, shareholders of Entasis will receive only $2.20 in cash for each share of Entasis that they own. KSF is seeking to determine whether this consideration and the process that led t

ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX

Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash.  Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock.

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

BURLINGAME, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the companies have entered into a definitive merger agreement under w

Innoviva to Acquire Entasis Therapeutics

Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the first quarter ended March 31, 2022. Gross royalty revenues of $93.5 million from Glaxo Group Limited (“GSK”) for the first quarter of 2022 included royalties of $55.8 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $8.4 million from global net sales of ANORO® ELLIPTA® and royalties of $29.3 million from global net sales of TRELEGY® ELLI

News for Innoviva Stock (INVA)